Principia Biopharma Inc.
(NASDAQ GS: PRNB)
Attention investors who purchased shares of Principia Biopharma Inc. before August 17, 2020:
Rigrodsky & Long is investigating potential claims against the board of directors of Sanofi Biopharma Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Sanofi.
Rigrodsky & Long, P.A. announces that it is investigating Principia Biopharma Inc. (“Principia”) (NASDAQ GS: PRNB) regarding possible breaches of fiduciary duties and other violations of law related to Principia’s agreement to be acquired by Sanofi (NASDAQ GS: SNY) in a transaction value at approximately $3.68 billion. Under the terms of the agreement, shareholders of Principia will receive $100.00 in cash for each share of Principia they own.
If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.